Breastfeeding in 2014: Has the Pendulum Swung Too Far?

ABSTRACT & COMMENTARY

By Rebecca H. Allen, MD, MPH

Assistant Professor, Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Women and Infants Hospital, Providence, RI

Dr. Allen reports no financial relationships relevant to this field of study.

Synopsis: This review outlines steps that OB/GYNs can take to support their patients who desire to breastfeed. Certain interventions — such as skin-to-skin care at birth, rooming-in for mother and infant postpartum, and avoiding formula feeding — are beneficial for initiating breastfeeding. OB/GYNs can also help women maintain breastfeeding after they leave the hospital by managing the perception of low milk supply and any complications.


This is a review of breastfeeding and how obstetrician-gynecologists can support women who desire to breastfeed at different stages: antepartum, intrapartum, and postpartum. Breastfeeding exclusively to 6 months of infant life is recommended by most major medical organizations, and the American Academy of Pediatrics encourages breastfeeding to at least 1 year. The author recommends asking an open-ended question, “What have you heard about breastfeeding?” Ideally, this is asked early in pregnancy, given that most women have already decided then how to feed their infant. Intrapartum care is one of the most important pieces to facilitate breastfeeding initiation. A na-

May Supplements Available Online

The May 2014 issues of Pharmacology Watch and Clinical Briefs in Primary Care are now available exclusively by e-mail or online. You can access these two valuable supplements to OB/GYN Clinical Alert at http://www.ahcmedia.com/supplements/.
Obstetrics, gynecology, and breast careینة، the author suggests that OB/GYNs can assess breast
succeed at exclusively breastfeeding. At postpartum vis
observation. Other steps include having a written supportive
breastfeeding policy for the hospital, training health
skills necessary to help women breastfeed
in the skills necessary to help women breastfeed
(INCLUDING providers and nurses), giving breastfeeding
CME activity is intended for the OB/GYN. It is in effect for 36
credit commensurate with the extent of their participation in the activity.
Physicians should claim only the
which was currently undergoing the process to become Baby-
levels of environmental toxins.” It is difficult to isolate
the effect of breastfeeding given these circumstances.
Nevertheless, increasing breastfeeding rates has become a
national policy goal, and hospitals and providers can play
part, as this article reviews. I have firsthand knowledge
part of the The Baby-Friendly Hospital Initiative as my hospi
Consultant is recommended for any difficulties. Given
that postpartum depression and anxiety can impact breast-
feeding, the author recommends that providers screen for
these issues and use the selective serotonin reuptake in-
hibitor, sertraline, if needed for therapy, since it is safe
with breastfeeding. The perception of low milk supply is
often a cause of premature weaning, so it can be helpful to
educate the patient and her family that feeding every 1-2
hours is normal for infants. There is no good evidence that
galactogogues are safe and facilitate milk supply.

■ COMMENTARY

The rate of breastfeeding initiation over time in the
United States has fluctuated from 70% in the early 1900s,
to 22% in the 1970s, and back up to 77% in 2010. In 2013,
the proportion of women with any breastfeeding com-
pared to exclusive breastfeeding at 6 months was 49% and
16.4%, respectively. There is no doubt that breastfeeding
is beneficial in many ways to the health and well being
of mothers and infants, as well as providing an environ-
mentally friendly and “free” food for infants. However,
whether breastfeeding is causally related to the many
health benefits its supporters claim, is still up for debate,
even though it may be heresy to say so. After all, there
are not likely to be many randomized, controlled trials on
the subject and observational epidemiology has its limita-
tions, especially confounding factors. As Colen et al note,
“Compared to bottle-fed infants, breastfed infants are sig-
ificantly more likely to be white, be born into families
with above average incomes, have parents with advanced
educational attainment, maintain easier access to health
care services, and live in safer neighborhoods with lower
levels of environmental toxins.” It is difficult to isolate
the effect of breastfeeding given these circumstances.
Nevertheless, increasing breastfeeding rates has become a
national policy goal, and hospitals and providers can play
a part, as this article reviews. I have firsthand knowledge
of the The Baby-Friendly Hospital Initiative as my hospi-
tal is currently undergoing the process to become Baby-
Friendly Certified. I sometimes wonder if that means we
were “Baby-Unfriendly” before!

This article outlines certain practices that providers
and hospitals can take to encourage breastfeeding. This
is certainly admirable and we should support mothers
who want to breastfeed, but what about those who do not or
cannot? I feel that the pendulum toward breastfeeding and
against formula has swung so far that women now feel
guilty and like a failure if they cannot exclusively breast-
feed their infants or have difficulties establishing a milk
supply. After all, as Colen et al point out, “Total com-
mittment to 6 months of exclusive breastfeeding is a very
high expectation of mothers, especially in an era when a
majority of women work outside the home, often in jobs
with little flexibility and limited maternity leave, and in

AHC Media

questions & Comments
Contact Leslie Coplin, Executive Editor, at leslie.coplin@ahcmedia.com.

Copyright © 2014 by AHC Media LLC. All rights reserved.
No part of this newsletter may be reproduced in any form or
incorporated into any information-retrieval system without the
written permission of the copyright owner.

Subscriber Information
Customer Service E-Mail: customerservice@ahcmedia.com

Subscription Prices
United States
Print 1-year with free AMA Category 1 credits: $49
Add $19.99 for shipping & handling
Online only, single issue: 1-year with free AMA Category 1 credits: $29

Multiple Copies
Discounts are available for group subscriptions, multiple copies,
site-licenses or electronic distribution. For pricing information, call
Tria Kreutzer at 404-262-5482.

Canada
Add 7% GST and $5 shipping.
Elsewhere
Add $5 shipping.

Accreditation
AHC Media is accredited by the Accreditation Council for Continuing
Medical Education to provide continuing medical education for
physicians.
AHC Media designates this enduring material for a maximum of 25
AMA PRA Category 1 Credits ™. Physicians should claim only the
credit commensurate with the extent of their participation in the activity.
This CME activity is intended for the OB/GYN. It is in effect for 36
months from the date of the publication.

POSTMASTER: Send
address Changes to
OB/GYN Clinical Alert,
P. O. Box 550669,
Atlanta, GA 30355.

OB/GYN Clinical Alert is published
monthly by AHC Media LLC, One Atlanta Plaza, 950 East Paces
Forest Road NE, Suite 2050, Atlanta, GA 30326.
EXECUTIVE EDITOR: Leslie L. Coplin
MANAGING EDITOR: Neil L. Kimball
EDITORIAL DIRECTOR: Lee Landenberger
GST Registration Number: R1298370.
Periodicals Postage Paid at Atlanta, GA 30304 and at additional
mailing offices.

The Baby-Friendly Hospital Initiative “The Baby-Friendly Hospital Initiative”
is helping hospitals implement 10 practices that promote
breastfeeding. A few key interventions are skin-to-skin
care and breastfeeding within 1 hour at birth, both for
vaginal delivery and cesarean delivery patients; no paci-
fiers, except for analgesic benefit during circumcision or
other procedures; and having mothers and infants room
together postpartum. In essence, the newborn nursery
should be empty except for the few infants who need extra
observation. Other steps include having a written supportive
breastfeeding policy for the hospital, training health
placer and an International Board Certified Lactation
Consultant is recommended for any difficulties. Given
that postpartum depression and anxiety can impact breast-
feeding, the author recommends that providers screen for
these issues and use the selective serotonin reuptake in-
hibitor, sertraline, if needed for therapy, since it is safe
with breastfeeding. The perception of low milk supply is
often a cause of premature weaning, so it can be helpful to
educate the patient and her family that feeding every 1-2
hours is normal for infants. There is no good evidence that
galactogogues are safe and facilitate milk supply.

a country that offers few family policies to support new-
borns or their mothers.”

Some of the intrapartum and postpartum steps to obtain Baby-Friendly Hospital status and support breastfeeding initiation make perfect sense. For example, skin-to-skin care and letting the infant latch within an hour after birth is great bonding for the mother and child. In addition, women who have to be separated from their infant (e.g., due to prematurity) can be taught how to pump milk to es-

establish their milk supply. The rooming-in idea stems from the fact that infants normally feed every 1-2 hours so the infant needs to be in the same postpartum room as the mother, not down the hall in the nursery. For most women and families, this is manageable and our patients are now advised antepartum what to expect about rooming in during their hospital stay. Some hospitals have even closed their newborn nurseries! Nevertheless, the obstetrician in me, being very protective of my patients, feels that wom-

en who have been through arduous labors or cesarean de-

liveries with complications, need to be able to rest and heal. They may not have a willing partner who can take care of the infant in their hospital room while they sleep. In these situations, I think the postpartum nurses, can and should, take care of the infant. I have been told that the goal is 80% rooming-in for Baby Friendly Hospital status and that exceptions can be made. My larger issue with the Baby Friendly Hospital designation is that while it may help initiate breastfeeding, maintenance is another matter entirely. Once the patient goes home, unless they can afford or have insurance coverage for lactation consultants, they are often on their own, figuring out how to maintain breastfeeding. Certainly, unpaid maternity leave and hav-
ing to go back to work 4 or 6 weeks postpartum does not help. I feel that until we, as a society, begin to value wom-

en and infants by providing paid maternity and paternity leaves, our national breastfeeding goal will go unfulfilled. While the Affordable Care Act now covers lactation counsel-
ing and costs for renting breastfeeding equipment, that does not solve other societal barriers. For my patients who are having difficulty breastfeeding, I certainly refer them to lactation consultants and support them, but I also validate how difficult it can be and reassure them that they are not bad mothers if they cannot continue.

Finally, I would challenge the author of this review on the effect of hormonal contraception on breastfeeding. I agree that we don’t have enough data to say that progestin-only methods absolutely do not affect breast-
feeding initiation or maintenance when given less than 6 weeks postpartum. But at the same time, as a physiologic process, so many factors affect breastfeeding (mode of delivery, medications, stress, anatomy, the infant, etc.) that isolating hormonal contraception as the main culprit seems dubious. This is especially important in populations with high unintended and repeat pregnancy rates.

These women and their current children might be better served by highly effective contraception and less breast-
feeding than having another child within 1 year of their delivery. For many women, the idea that they will be able to breastfeed exclusively and use lactational amenorrhea for contraception is a fantasy. We often administer depot medroxyprogesterone acetate or the etonogestrel implant to our patients before they are discharged postpartum so that they can be protected against rapid repeat pregnancy, and this is supported by the United States Medical Eligibility Criteria for Contraceptive Use.

References

Does Antibiotic Prophylaxis Prevent Postoperative UTIs in Patients Requiring Short-term Catheterization?

ABSTRACT & COMMENTARY

By Chiara Ghetti, MD

Associate Professor, Obstetrics and Gynecology, Division of Female Pelvic Medicine and Reconstructive Surgery, Washington University School of Medicine, St. Louis, MO

Dr. Ghetti reports no financial relationships relevant to this field of study.

Synopsis: After pelvic floor reconstructive surgery, antibiotic prophylaxis with daily nitrofurantoin during postoperative catheterization does not decrease risk of urinary tract infection.


CATHETER-RELATED URINARY TRACT INFECTIONS (UTI) ARE the most frequent hospital-acquired infections. The estimated risk of UTI following pelvic reconstructive sur-
surgery is 5-35%. This study attempted to answer the question of whether antibiotics effectively decrease the risk of UTI in patients requiring catheter drainage following reconstructive surgery.

This was a randomized, double-blind, placebo-controlled trial of patients undergoing surgery for pelvic organ prolapse and/or incontinence requiring postoperative catheterization. The primary outcome was defined as treatment for UTI within 3 weeks of surgery. English-speaking, non-pregnant patients age ≥ 21 years having surgery for pelvic floor disorders were enrolled. Patients undergoing surgery for urethral diverticulum, fistula repair, or sacral modulation or who had an intraoperative urinary tract injury were excluded. Women with an allergy to nitrofuratoin, creatinine clearance < 60 mL/min, or preoperative urinary retention requiring catheterization also were excluded. Subjects requiring postoperative catheterization were randomized to receive daily nitrofurantoin prophylaxis vs placebo for 7 days starting on postoperative day 1. These included all subjects hospitalized postoperatively with Foley catheter drainage as well as all subjects discharged on day of surgery with Foley catheter or performing clean intermittent self-catheterization. All subjects received guideline-recommended perioperative antibiotic prophylaxis prior to the start of surgery. Treatment for UTI was defined as treatment for either clinically suspected or culture-proven infection. Multiple methods (including query of medical record, postoperative visits, and completion of forms by outside facilities) were used to determine whether UTI treatment had occurred in the 3 weeks following surgery. Sample size calculation estimated that 156 participants were necessary to demonstrate a two-thirds reduction in risk of UTI.

The study enrolled 375 subjects, of which 163 were randomized. Four randomized subjects were excluded from final analysis for protocol deviations. Final analysis included 159 subjects, 81 in the nitrofurantoin treatment group and 78 in the placebo group. Baseline and perioperative characteristics were not different between groups. Groups were also not different in duration or type of catheter use after surgery.

The risk of UTI in the 3 weeks following surgery was 18% in all subjects (28/159). The risk was not different between nitrofurantoin (22%) vs placebo groups (13%) (relative risk 1.73; 95% confidence interval [CI], 0.85-3.52; P = 0.12). Of those treated, 68% were treated for a culture-proven UTI and 32% were treated empirically for a clinically suspected UTI. Using regression analysis, there was no difference in risk of UTI when controlling for menopausal status, diabetes, preoperative post-void residual, creatinine clearance, hysterectomy, and duration of catheterization. The authors conclude that nitrofurantoin prophylaxis for each day of catheterization does not reduce UTI risk in patients undergoing reconstructive pelvic surgery requiring short-term transurethral catheterization.

**COMMENTARY**

UTIs account for 40% of hospital-acquired infections and the majority (80%) of these are associated with the use of indwelling catheters. Catheter-associated urinary tract infections (CAUTI) can be associated with increased morbidity and mortality, increased hospitalization, as well as increased health care costs. CAUTI have received increased attention in recent years with the publication of numerous guideline documents and adoption of quality measures. In 2009, as part of National Hospital Inpatient Quality Measures, removal of catheter on postoperative day 1 or 2 was added as a Surgical Care Improvement Project (SCIP) measure to improve surgical care by reducing surgical complications. In 2012, the Joint Commission published a new National Patient Safety Goal specific to CAUTI based on the Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute Care Hospitals and the CDC Guideline for Prevention of Catheter-associated Urinary Tract Infections. In January 2013, there was full implementation of CAUTI surveillance of evidence-based practices to prevent indwelling CAUTI.

The main tenets employed to reduce CAUTI are to avoid unnecessary catheterization and to limit duration of catheterization. Due to antibiotic side effects and risk of antimicrobial resistance, the role of prophylactic antibiotics has been debated. The 2013 Cochrane review concluded that there is limited evidence suggesting that receiving prophylactic antibiotics reduces the rate of bacteriuria and other signs of infection in surgical patients who undergo bladder drainage for at least 24 hours postoperatively. This randomized, double-blind, placebo-controlled study found that nitrofurantoin prophylaxis during time of catheterization following reconstructive surgery did not reduce the risk of UTI. While this well-designed study adds important information regarding this clinical dilemma, what remains unanswered is whether antibiotic prophylaxis with another agent or whether prophylaxis that extends beyond the period of catheterization would reduce UTI risk in this population.

**References**

Special Feature

Nausea and Vomiting in Pregnancy

By John C. Hobbins, MD

Professor, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora

Dr. Hobbins reports no financial relationships relevant to this field of study.

Synopsis: A variety of methods and medications are available to treat nausea and vomiting in pregnancy — one of the most common and often vexing problems for pregnant women. Although most of these have had anecdotal suggestion of benefit and documented suggestions of efficacy through randomized trials, some have had limited exposure to investigations involving safety.

Since about three-quarters of pregnant patients will experience some episodes of nausea and vomiting in the first trimester and sometimes further, this Special Feature has been fashioned to help the clinician deal with something that can be difficult for many patients to endure, but also challenging for providers to treat. Fortunately, only about 1-2% of patients will have the very severe form, hyperemesis gravidarum (HG), where there is accompanying weight loss (> 5% of body weight), dehydration, electrolyte imbalance, and ketosis — any of which could require hospitalization.

Some have attempted to categorize the severity of nausea and vomiting in pregnancy (NVP) according to the number of episodes of vomiting per day. For example, mild is described as 1-2 episodes per day lasting < 1 hour; severe is more than 5 episodes of vomiting per day with symptoms lasting for > 5 hours. In some studies, a severity scoring system — the Pregnancy-Unique Quantification of Emesis and Nausea — has been employed, but clinically it is hard to put a number on the degree of discomfort.

Although the timing of nausea and vomiting episodes has resulted in the term “morning sickness,” in some patients it also could be easily described as “afternoon” or “evening sickness,” leaving some patients completely incapacitated for most of the day. In fact, because of this, it has been estimated that the economic loss of this condition is between $3000 and $17,000 for patients suffering from the severe variety.

Reasons for NVP

NVP symptoms are temporally related to the rise in hCG and estrogen. Patients with twins, molar pregnancies, and those assisted reproductive technology patients with ovarian hyperstimulation (all having sky-high hCG levels) are particularly susceptible to severe NVP.

Psychological factors can play a role either on the front end or, certainly, as a result of the NVP. Hyperthyroidism has been blamed on occasion (falsely) because pregnancy, in general, causes a hypermetabolic state with a rise in T4 and decrease in thyroid-stimulating hormone. Also, hCG may have an independent thyroid-like effect in pregnancy.

Diagnosis

Since NVP is so common, most clinicians will not pursue other reasons for the symptoms until the condition becomes problematic. Another cause may be suspected if the symptoms start before the fifth week or persist well past 14 weeks — and the gastrointestinal (GI) tract is the logical place to start. However, by the time this diagnostic pathway is explored, one cannot tell whether the upper GI symptoms/signs of gastric reflux or esophagitis are primary or secondary factors.

There has been an attempt to link Helicobacter pylori with NVP and HG, since a majority of these patients have H. pylori antibodies. However, there is no correlation with this antibody level and the duration of symptoms.

Treatment

Since NVP has been occurring through the ages, there have been more home remedies and concoctions for this than attempted cures for hiccups. I apologize that some of the following information is not new to providers. Below is an up-to-date assortment of therapeutic measures, a few of which have undergone some scientific scrutiny, but many others based predominantly on anecdotal experience alone.

Food and Fluid Intake. An empty stomach should be avoided. Small, frequent meals every 1-2 hours helps. If fluids are not tolerated with feedings, then fluid intake should be given between feedings to eventually attain a recommended threshold of eight glasses per day. With fluid intake, the colder the better, and many affected women have effectively used popsicles to counter dehydration. Sport drinks are often well tolerated and will replace lost electrolytes.

Although some have advocated ingestion of food with high carbohydrate content, there is a suggestion that protein triggers less gastric reflux. There is evidence that avoiding spicy or acid-generating foods, noxious odors,
cigarette smoke, or some perfumes is helpful. Chewable antacid tablets can have definite benefit while also replacing calcium and magnesium.

**Vitamins.** Vitamins, in general, are needed for many pregnant patients and may lessen the chances of having NVP, especially if taken before 6 weeks. However, vitamins spiked with iron may have the opposite effect, since iron is a common trigger of nausea and vomiting. There is no doubt that some women require supplemental iron, but in most cases it is not essential in the first trimester. Therefore, it is worth switching to an iron-less option such as a children’s chewable vitamins. At least one randomized trial has shown significant improvement in NVP in women taking non-iron containing prenatal vitamins.

Folic acid is necessary for the reduction of neural tube defects (NTD) and can be taken separately in women who find the typical prenatal vitamin contributory to their NVP. Most prenatal vitamins have 800 ug of folic acid, which is more than the minimal daily dietary requirement of 400 ug (CDC recommendation). However, individuals at risk for NTDs (diabetes, obesity, or previous child with NTD) have been advised to take 4000 ug (4 mg) of additional folic acid per day.

Most importantly, pyridoxine (vitamin B6) alone has been shown to be of benefit in diminishing nausea and vomiting as a first step remedy and has not been associated with adverse fetal effect.

**Medications.** Often prescribed for motion sickness, the most frequent first-line medications for NVP are the antihistamine H1 blockers: doxylamine (Unisom), meclizine (Antivert), dimenhydrinate (Dramamine), and promethazine (Phenergan). They stabilize the vestibular system while modifying stimuli to the vomiting center. Doxylamine is unlisted according to FDA classifications and, with the exception of promethazine, which has a class C listing, the others are in a class B category.

None of the H1 blockers has been shown to have teratogenic effect, and with pooled data from studies evaluating different antihistamines, there was an improvement in symptoms of NVP by about 70%. Maternal side effects include drowsiness, dry mouth, and rare extra-pyramidal effects. Since H1 blockers have weak anticholinergic properties, they should be used with caution in those with asthma, glaucoma, or pre-glaucoma.

The doxylamine story is worth telling. It was a component of a formula specifically designed for NVP when combined with dicyclomine (an antispasmodic) and vitamin B6. For many years, up to 25% of pregnant patients were using this medication, which bore the brand name Bendectin®. There was good documentation of its efficacy and there never was any scientific evidence of teratogenicity. However, in the 1980s, some lawsuits surfaced with claims that Bendectin® caused various birth defects. Of those going forward, none ended in favor of the plaintiff, but, despite the drug’s vindication in every case, the company chose to take it off the market rather than to engage in, seemingly, never-ending, expensive litigation. Undaunted, many clinicians reverted to the use of doxylamine alone, marketed as a sleeping aid (Unisom) with or without vitamin B6. A company has been making this combination (doxylamine and B6) in Canada under the name Diclectin, and very recently the FDA has approved its use in the United States (class A) under the label Diclegis.

**Serotonin Antagonists.** Often used in chemotherapy, a medication that has recently gained momentum in treating refractory NVP is a serotonin antagonist, ondansetron (Zofran®). This drug works by blocking the chemoreceptor trigger zone in the medullary vomiting center. Although anecdotal evidence abounds regarding its efficacy in cases of HG, there is a paucity of available randomized data. It carries a class C designation. An initial suspicion of it being linked with cleft lip and palate has not been subsequently validated. Also, the FDA has warned about the rare possibility of an association with lengthening of the QT interval, especially in patients with pre-existing cardiovascular problems.

**Dopamine Antagonists.** In this category are the phenothiazines, which have antipsychotic as well as antiemetic properties. More commonly used are the phenothiazines, prochlorperazine (Compazine) and chlorpromazine (Thorazine), both carrying Class C labels. Another in this category is the class C benzamide, metoclopramide (Reglan). Combined data from three older randomized, placebo-controlled studies showed significant benefit of the phenothiazines in NVP. Safety data, however, have been inconsistent and prolonged use can be associated with withdrawal in newborns and extra-pyramidal affects.

Also working on the vomiting trigger center through dopamine receptors, trimethobenzamide (Tigan) and metoclopramide have been used as second-line drugs in refractory NVP and have class C and B listings, respectively. Yet few data exist regarding their efficacy.

**Steroids.** Methylprednisolone (prednisone) has been used as a last-ditch treatment for HG, but rarely for milder NVP. Interestingly, although one study showed this drug to be superior to promethazine in treating HG, especially regarding rates of re-hospitalization, another later randomized, controlled trial found no difference in the rate of re-hospitalization with this steroid vs placebo. Initially, there was a question of a linkage with cleft lip and palate, but this risk is low (1-2 per 1000 treated). However, its potential adverse neonatal and maternal effects (on the adrenal) should make this mostly a last-resort, short-term strategy for hospitalized patients.

**Alternative Therapies.** Lifestyle changes. Avoidance
of a stressful environment is easy to prescribe but often difficult to accomplish. The catalyst to NVP is often the home environment, which could be a major reason hospitalization is effective. Unfortunately, providing an alternate living setting is often not practical.

Ginger Root. Thought to have a direct effect on the GI system, the lay literature is replete with testimonials of the efficacy of ginger root in curbing NVP. Many RCTs have suggested its benefit in NVP compared with placebo controls, but others have shown no added benefit over pyridoxine alone. In the treatment of HG, a more recent RCT showed improvement in nausea (85% vs 56%) and vomiting (50% vs 9%) with ginger root compared with placebo. There has been no evidence of adverse fetal effects but since there is some suspicion that ginger root can interfere with maternal platelet aggregation, it may not be the first choice in patients on low-dose aspirin or anticoagulants.

Acupuncture. For NVP, the Nguian acupoint on the inner wrist (P6) has been the focus of attention for either pressure via a wristband (either with pressure alone or with acoustic stimulation) or an acupuncturist’s needle. Efficacy studies have had conflicting results, and randomized trials have been hindered by the lack of adequate controls. However, a recent randomized trial from Australia did show benefit of acupuncture delivered in two ways. Smith et al assigned 593 patients with NVP to having traditional acupuncture, P6 acupuncture, sham procedures, or no treatment (controls). Both types of acupuncture caused a lessening of nausea, vomiting, and dry retching vs controls. Interestingly, the sham approach reduced nausea and dry retching, but not vomiting.

Marijuana (cannabis). Living in Colorado where marijuana has recently been legalized, how can I not mention this as an alternative to reduce unresponsive NVP? It has been used on occasion to reduce nausea and vomiting from chemotherapy. However, although one can find glowing anecdotal accounts online regarding its use in severe NVP, evidence-based information is difficult to come by — mostly because investigators are reluctant to stray into this highly charged social and political arena.

As an example of the only type of information available on efficacy, in a published survey from British Columbia (the Vancouver Island Compassion Society), 84 pregnant women responded anonymously to a questionnaire and 36 admitted to using marijuana to curb nausea and vomiting. Ninety-two percent claimed they found it to be either “extremely effective” or “effective.”

A few studies have explored possible adverse effects of marijuana. One often-quoted follow-up investigation involved infants of Jamaican mothers who had prenatal exposure to marijuana (ganja), where, despite being illegal, it is commonly used to combat NVP. There were no differences in birth weight or in neurological testing (by the Brazelton scale analysis) at 3 days of age in exposed compared with control neonates. Ill-conceived bumper sticker material could spring from the puzzling finding that the marijuana-exposed infants tested better neurologically after 30 days than controls — which may well have been due to socioeconomic factors. Surveys of 12,060 British women in 2002, 12,885 Dutch women in 1999, as well as 32,483 mothers in Australia in 1997 found no differences in birth weights in marijuana users vs controls after accounting for confounding variables.

Obviously, birth weight is one endpoint to evaluate because of the association between cigarette smoking and intrauterine growth restriction, but more extensive testing would be needed to clear marijuana of a possible effect on the fetal CNS, a possibility suggested by some cognitive studies in children exposed in utero during sustained use, but not others. Nevertheless, in special cases the potential benefit of this short-term approach cannot be easily pushed aside.

Table 1. Simplified Approach to Treating NVP

<table>
<thead>
<tr>
<th>First-line approach:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Dietary manipulation</td>
</tr>
<tr>
<td>2. Vitamin adjustment</td>
</tr>
<tr>
<td>3. Pyridoxine (B6), 25 mg TID</td>
</tr>
<tr>
<td>4. Doxylamine (Unisolom), 10-20 mg HS</td>
</tr>
<tr>
<td>5. Diclegis (instead of 3 and 4), 1-2 tabs HS or up to 5 per day</td>
</tr>
<tr>
<td>6. Ginger root, 250 mg QID</td>
</tr>
<tr>
<td>7. Acupressure band</td>
</tr>
<tr>
<td>8. Avoidance of work or home stressors</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Second-line approach (if NVP not improved after 5-7 days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Another H1 blocker such as dimenhydrinate (Dramamine), 25-50 mg q 4-6 hrs; promethazine (Phenergan), 12.5-25 mg TID; or meclizine (Antivert), 25 mg q 4-6 hr</td>
</tr>
<tr>
<td>2. A phenothiazine such as prochlorperazine (Compazine), 5-10 mg QID, or another dopamine antagonist such as metoclopramide (Reglan), 5-10 mg TID</td>
</tr>
<tr>
<td>3. A serotonin antagonist such as ondansetron (Zofran), 4-8 mg TID</td>
</tr>
<tr>
<td>4. Acupuncture</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Third-line treatment (if all else fails)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Hospitalize if weight loss of &gt; 5% of original body weight, significant dehydration, or electrolyte imbalance.</td>
</tr>
<tr>
<td>2. IV hydration and correction of electrolyte imbalance</td>
</tr>
<tr>
<td>3. Explore H. pylori (with GI consultation) as a cause and treat if there is a suspicion of causation</td>
</tr>
<tr>
<td>4. Consider steroids: methylprednisolone 16 mg TID x 3 days, then taper</td>
</tr>
<tr>
<td>5. Short-term parenteral nutrition may be necessary</td>
</tr>
</tbody>
</table>
Complications of NVP

Severe NVP can occasionally develop into some very serious complications, such as vitamin deficiency (especially thiamin) resulting in conditions such as Wernicke syndrome, as well as hypokalemia, acid-base imbalance, and impressive maternal weight loss. One study has shown that women with HG who gained < 15 pounds have a higher rate of low birth weight infants and lower 5-minute Apgar scores. While not having an obvious effect on neurological outcome at 1 year of age, there is a higher rate of low birth weight, preterm birth, and SGA infants. Based on the known possible complications of intractable NVP, and its significant disruptive effect on patients and their families, one cannot ignore the known benefits of some second- and third-line therapies when compared with their unknown or unlikely risks. Table 1 represents a simplified approach to the treatment of NVP.

References

CME Questions

1. Which of the following is not one of the 10 hospital practices to encourage and support breastfeeding?
   a. Rooming-in of mothers and infant after birth
   b. No pacifiers except for analgesic purposes for procedures
   c. Offer mothers the opportunity to initiate breastfeeding within 1 hour of giving birth
   d. Mandatory lactation consult for every postpartum mother
   e. Train all pertinent health care staff in the skills necessary to encourage breastfeeding

2. Which of the following statements is true concerning catheter-related urinary tract infections?
   a. Catheter-related urinary tract infections are not very common.
   b. The best way to prevent catheter-related urinary tract infections is to give antibiotics to all patients with a catheter.
   c. Decreasing unnecessary catheterization and decreasing length of catheterization are main tenets employed to reduce catheter-related urinary tract infection.
   d. All of the above are true.

3. Doxylamine in combination with vitamin B6 is effective in the treatment of nausea and vomiting in pregnancy.
   a. True
   b. False

In Future Issues:

"An aspirin a day keeps the ovarian cancer away..."
In an effort to ensure *OB/GYN Clinical Alert* is addressing the issues most important to you, we ask that you take a few minutes to complete and return this survey. The result will be used to ensure you are getting the information most important to you.

**Instructions:** Mark your answers by filling in the appropriate bubbles. Please write in your answers to the open-ended questions in the space provided. Either fax the completed questionnaire to 404-492-5933, or return it in the enclosed postage-paid envelope. The deadline is July 1, 2014.

Following is a list of topics frequently discussed in *OB/GYN Clinical Alert*. To help us understand your needs, please fill in the appropriate answer to indicate your interest in that topic.

<table>
<thead>
<tr>
<th>Topic</th>
<th>A. very useful</th>
<th>B. fairly useful</th>
<th>C. not very useful</th>
<th>D. not at all useful</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. HRT issues/concerns</td>
<td>○ A</td>
<td>○ B</td>
<td>○ C</td>
<td>○ D</td>
</tr>
<tr>
<td>2. Contraception</td>
<td>○ A</td>
<td>○ B</td>
<td>○ C</td>
<td>○ D</td>
</tr>
<tr>
<td>3. Ovarian cancer</td>
<td>○ A</td>
<td>○ B</td>
<td>○ C</td>
<td>○ D</td>
</tr>
<tr>
<td>4. Breast cancer</td>
<td>○ A</td>
<td>○ B</td>
<td>○ C</td>
<td>○ D</td>
</tr>
<tr>
<td>5. Cervical cancer</td>
<td>○ A</td>
<td>○ B</td>
<td>○ C</td>
<td>○ D</td>
</tr>
<tr>
<td>6. Pap smear testing</td>
<td>○ A</td>
<td>○ B</td>
<td>○ C</td>
<td>○ D</td>
</tr>
<tr>
<td>7. Postmenopausal patients</td>
<td>○ A</td>
<td>○ B</td>
<td>○ C</td>
<td>○ D</td>
</tr>
<tr>
<td>8. Labor/delivery complications</td>
<td>○ A</td>
<td>○ B</td>
<td>○ C</td>
<td>○ D</td>
</tr>
<tr>
<td>9. Bone density</td>
<td>○ A</td>
<td>○ B</td>
<td>○ C</td>
<td>○ D</td>
</tr>
<tr>
<td>10. Cesarean section</td>
<td>○ A</td>
<td>○ B</td>
<td>○ C</td>
<td>○ D</td>
</tr>
</tbody>
</table>

11. What other topics would you like to see discussed in *OB/GYN Clinical Alert*? ____________________________________________________________

12. Are the articles in *OB/GYN Clinical Alert* written about issues of importance and concern to you?
   ○ A. always ○ B. most of the time ○ C. some of the time ○ D. rarely ○ E. never

13. What type of information not currently provided in *OB/GYN Clinical Alert* would you like to see added? ____________________________________________________________

Please rate your level of satisfaction with the items listed. Please mark your answers in the following manner:

<table>
<thead>
<tr>
<th>Item</th>
<th>A. excellent</th>
<th>B. good</th>
<th>C. fair</th>
<th>D. poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>14. quality</td>
<td>○ A</td>
<td>○ B</td>
<td>○ C</td>
<td>○ D</td>
</tr>
<tr>
<td>15. article selections</td>
<td>○ A</td>
<td>○ B</td>
<td>○ C</td>
<td>○ D</td>
</tr>
<tr>
<td>16. timeliness</td>
<td>○ A</td>
<td>○ B</td>
<td>○ C</td>
<td>○ D</td>
</tr>
<tr>
<td>17. quality of commentary</td>
<td>○ A</td>
<td>○ B</td>
<td>○ C</td>
<td>○ D</td>
</tr>
<tr>
<td>18. clearness of abstracts</td>
<td>○ A</td>
<td>○ B</td>
<td>○ C</td>
<td>○ D</td>
</tr>
<tr>
<td>19. overall value</td>
<td>○ A</td>
<td>○ B</td>
<td>○ C</td>
<td>○ D</td>
</tr>
<tr>
<td>20. customer service</td>
<td>○ A</td>
<td>○ B</td>
<td>○ C</td>
<td>○ D</td>
</tr>
</tbody>
</table>
21. Are the articles in *OB/GYN Clinical Alert* newsletter:
   - A. too short
   - B. too long
   - C. about right

22. To what other publications or information sources about OB/GYN issues do you subscribe?

23. Including *OB/GYN Clinical Alert*, which publication or information source do you find most useful, and why?

24. Please describe your workplace:
   - A. private practice
   - B. hospital
   - C. government institution
   - D. research
   - E. Other

25. Do you have Internet access at work?
   - A. yes
   - B. no

26. Would you like to receive *OB/GYN Alert* via e-mail?
   - A. yes
   - B. no

27. If you would you like to receive *OB/GYN Alert* via e-mail, please provide your e-mail address:

28. How much time do you spend accessing job-related information via on-line services (Email list servs, web site, etc)?
   - A. 0 hours per week
   - B. 1-5 hours per week
   - C. 6-10 hours per week
   - D. more than 11 hours per week

29. In the future, how do you plan to obtain your CME credits?
   - A. travel to live conferences
   - B. subscription-based newsletters/journals
   - C. outside-sponsored teleconferences
   - D. Internet-based activities
   - E. Other (please specify)

30. List the top three challenges you face in your job today.

   1. 
   
   2. 
   
   3. 

Contact information